Hemodynamic effects of a new type III phosphodiesterase inhibitor (CI-914) for congestive heart failure

This publication has 17 references indexed in Scilit:

• Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement.
  Circulation, 1985
• Selective inhibitors of three forms of cyclic nucleotide phosphodiesterases
  Trends in Pharmacological Sciences, 1984
• Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure.
  Circulation, 1984
• Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in patients with chronic heart failure
  Journal of the American College of Cardiology, 1984
• Evaluation of a New Bipyridine Inotropic Agent — Milrinone — in Patients with Severe Congestive Heart Failure
  New England Journal of Medicine, 1983
• The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure.
  Circulation, 1983
• Intermittent, continuous outpatient dobutamine infusion in the management of congestive heart failure
  The American Journal of Cardiology, 1983
• Long-term amrinone therapy in patients with severe heart failure
  The American Journal of Medicine, 1982
• Hemodynamic effects of intravenous prenalterol in severe heart failure
  The American Journal of Cardiology, 1981
• Improved radioimmunoassay of platelet factor 4 and β-thromboglobulin in plasma
  Clinica Chimica Acta; International Journal of Clinical Chemistry, 1980